

DMB
Display Date 2-28-02
Publication Date 3-1-02
Certifier D. Hawkins

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Joint Meeting of the Gastrointestinal Drugs Advisory Committee
and the Drug Safety and Risk Management Subcommittee of the
Advisory Committee for Pharmaceutical Science; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public
advisory committee of the Food and Drug Administration (FDA).
The meeting will be open to the public.

Name of Committee: Gastrointestinal Drugs Advisory
Committee and the Drug Safety and Risk Management Subcommittee of
the Advisory Committee for Pharmaceutical Science.

General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on April 23, 2002,
from 8 a.m. to 5 p.m.


Location: Holiday Inn, Versailles Ballroom, 8120 Wisconsin
Ave., Bethesda, MD.

Contact Person: Thomas H. Perez, Center for Drug Evaluation
and Research (HFD-21), Food and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 30x-827-6758, e-mail at
PerezT@cder.fda.gov, or FDA Advisory Committee Information Line,
1-800-741-8138 (301-443-0572 in the Washington, DC area), code
12538. Please call the Information Line for up-to-date
information on this meeting. Background materials for this
meeting when available will be posted on the Internet one

business day before the meeting at
www.fda.gov/ohrms/dockets/ac/acmenu.htm.


Agenda: The committee will discuss risk management for new drug application (NDA) 21-107, LOTRONEX (alosetron), GlaxoSmithKline.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by April 15, 2002. Oral presentations from the public will be scheduled between approximately 11:30 a.m. and 12:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before April 15, 2002, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.



Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.


FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Thomas Perez at least 7 days in advance of the meeting.



Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).

Dated 2-22-02

February 22, 2002.



Linda A. Suydam,
Senior Associate Commissioner for
Communications and Constituent
Relations.

[FR Doc. 02-????? Filed ??-??-02; 8:45 am]

BILLING CODE 4160-01-P

**CERTIFIED TO BE A TRUE
COPY OF THE ORIGINAL**

Dawn P. Hawkins